Microbix Biosystems Inc (MBXBF)

[yielddude]

Life Sciences Ontario Microbix summary from 11/22
Microbix is a profitable and growing, publicly-traded (TSX, OTCQX), awardwinning, Ontario-headquartered, world leader in the development and
manufacture of specific biotechnology solutions for human health. The
company has over 110 skilled employees based in Mississauga. It is currently
ISO9001- and ISO13485 (Medical Device)-accredited, has a Pathogen and
Toxin license issued by the Public Health Agency of Canada and a Medical
Device Establish License (MDEL) from Health Canada. The company’s current
34,000ft2
campus comprises R&D, manufacturing, and testing facilities.
The company makes a range of critical materials for the global diagnostics
industry, notably infectious disease antigens for diagnostic immunoassays and
its laboratory quality assessment products (QAPs™) that support clinical lab
proficiency testing, enable new test validation, or ensure the optimum accuracy
of testing in clinical diagnostics laboratories. Microbix’s antigens enable the
antibody tests of over 120 international diagnostics companies, while its QAPs
are sold to globally to clinical laboratory accreditation organizations, diagnostics
companies, and clinical laboratories.
BARRIERS TO SUCCESS
The health of Ontarians will be improved, and delivery costs reduced, if Ontario authorities
maintain a Quality- and Value-based approach to strategic procurement, with meaningful focus
on longer-term planning. Focus should also be on local procurement to support Ontarians and
mitigate future supply chain issues. This approach will allow Ontario companies to plan for
growth and more Ontarians to find high-quality employment.
KEY WINS
Microbix has more than doubled in size (footprint and staff) in the last 3 years. It provides
Ontarians with rewarding, high-quality jobs. Microbix’s current QAPs portfolio is now available
in over 30 countries. This encompasses over 200 separate products. Within these there are
currently over 30 fully-regulated IVD medical devices that ensure testing accuracy for human
diseases, including QAPs controls for all major variants of SARS-CoV-2 (COVID-19). Microbix
has received support from FedDev Ontario to support this growth. In response to the COVID-19
pandemic, and with a grant from the Ontario Together Fund (MEDJCT), Microbix applied its
expertise in sterile manufacturing, automation and quality management to produce a state-ofthe-art IVD viral transport medium (DxTMTM brand) to support COVID-19 (and other) testing in
Ontario. To date, Microbix has provided over 2 million units of this vital, locally-made, product
to the province. Microbix will continue helping Ontario and other provinces optimize infectiousdisease testing for respiratory viruses, sexually-transmitted infections, and other human
pathogens of concern.
LOOKING FORWARD
COVID-19 has amply demonstrated the need for locally-derived capabilities to manage human
infectious diseases. In future, other such diseases must be managed to support the health
of Ontarians. These include respiratory infections (RSV, Flu, etc.), gastrointestinal pathogens,
sexually-transmitted infections and antibiotic-resistant organisms. Microbix works in all of these
areas, and more. In the coming years, Microbix will continue its profitable growth and will acquire
further facilities and talented staff. The company intends to create a secure, Ontario-based
global leadership position for assuring the best possible testing for human infectious diseases.

https://lifesciencesontario.ca/wp-content/uploads/2022/11/Success-Stories-2022-FINAL.pdf